Maria Cancio

TL;DR: The data supports the safety of CD19-specific CAR T cell therapy for R/R B-ALL and suggest that dose intensity of conditioning chemotherapy and minimal pre-treatment disease burden have a positive impact on response without a negative effect on toxicity.

TL;DR: A single-center prospective screening study has shown that the incidence of Transplant-associated thrombotic microangiopathy (TA-TMA) is much higher than prior retrospective studies that did not systematically screen as discussed by the authors.

TL;DR: At least three inflammatory disorders or syndromes associated with immune dysfunction have been described in the context of cellular therapy and all have clinical and laboratory characteristics in common with COVID19 and associated therapies that could be worth testing in the contexts of clinical trials.

TL;DR: The relationship between early CD4+ T cell immune reconstitution (CD4+ IR) and survival after T-replete allogeneic hematopoietic cell transplantation (HCT) has been previously reported as mentioned in this paper.

TL;DR: Early CD4+ IR, a simple and robust markerpredictive of outcomes after HCT, associates with survival after moderate to severe aGvHD, and these associations need to be confirmed in a prospective manner but suggest that strategies to improve T-cell recovery after H CT may influence survival in patients developing aGVHD.